Hormone therapy is frequently utilized for the Luminal A and B subtypes, whereas anti‐HER2 monoclonal antibody therapy is considered the standard of care for HER2‐overexpressed breast cancer (Reinert and Barrios 2015; Wuerstlein and Harbeck 2017). Here, ERBB2 is linked to breast cancer.